Gain Therapeutics
GANX
23 hedge funds and large institutions have $3.95M invested in Gain Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 0 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
44% more funds holding
Funds holding: 16 → 23 (+7)
1.17% more ownership
Funds ownership: 9.05% → 10.21% (+1.2%)
2% more capital invested
Capital invested by funds: $3.87M → $3.95M (+$85.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$234K |
| 2 |
WAAG
Wealth Alliance Advisory Group
Wichita,
Kansas
|
+$93.9K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$90.2K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$47.1K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$44.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Telemetry Investments
New York
|
-$37.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$8.6K |
| 3 |
BlackRock
New York
|
-$2.4K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$376 |
GANX Hedge Fund Activity: Q3 2022 in Review
23 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q3 2022, worth a combined $3.95M — up 2.2% from $3.87M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new GANX positions and 0 closed out — a net gain of 7 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $234K. The largest seller was Telemetry Investments, cutting an estimated $37.6K.
- 23 institutional investors held Gain Therapeutics (GANX) as of Q3 2022, up from 16 in Q2 2022.
- Funds reported $3.95M of Gain Therapeutics stock for Q3 2022, up 2.2% quarter-over-quarter.
- 7 funds opened new Gain Therapeutics positions in Q3 2022 and 0 closed out, a net change of +7 holders.
- The largest Gain Therapeutics buyer in Q3 2022 was Geode Capital Management, an estimated $234K added.
- The largest Gain Therapeutics seller in Q3 2022 was Telemetry Investments, an estimated $37.6K sold.
Based on aggregated 13F filings for Q3 2022.